Abstract 338P
Background
Nasal type NKTCL refers to upper aerodigestive tract (UAT) involvement while non-nasal type does not involve UAT at initial diagnosis. Since NKTCLs are predominantly nasal type, there remains little knowledge of non-nasal type disease.
Methods
Newly diagnosed advanced-stage non-nasal and nasal type NKTCL patients from two large cancer centers in the past 10-15 years were retrospectively collected.
Results
The study included 56 non-nasal type NKTCL patients with 139 nasal cases as controls. The non-nasal type NKTCLs exhibited higher Ki-67 expression levels compared to nasal cases (P=0.011) with no significant differences in other baseline features. With a median follow-up of 75.03 months, the non-nasal group showed slightly inferior overall survival (OS) compared to the nasal group (median OS [mOS]: 14.57 vs. 21.53 months, P=0.120). ECOG score≥2 (hazard ratio [HR]=2.18, P=0.039) and LDH elevation (HR=2.44, P=0.012) were correlated with worse OS, and the modified nomogram-revised risk index (NRI) and international prognostic index (IPI) functioned effectively for prognostic stratification. Multi- compared to single-modality therapy led to significantly superior progression-free survival (PFS) and OS (median PFS [mPFS]: 11.53 vs. 2.03 months, P=0.001; mOS: 52.80 vs. 7.70 months, P=0.006). Chemoradiotherapy combination significantly improved survival compared to other modalities (mPFS: 14.00 vs. 3.47 months, P=0.050; mOS: 56.40 vs. 9.30 months, P=0.046), and gemcitabine- compared to non-gemcitabine-based regimens showed a trend towards slightly improved outcomes (mPFS: 10.43 vs. 3.40 months, P=0.106; mOS: 25.13 vs. 9.30 months, P=0.125). Table: 338P
Prognostic stratification of advanced-stage non-nasal type ENKTLs
Model | Variable | Risk stratification | Score | Non-nasal type (n=56) (%) | Nasal type (n=139) (%) |
Modified NRI | Age (>60 vs. ≤60 years)ECOG score (≥2 vs. 0-1) Elevated LDH (yes vs. no) | low risk | 0 | 16(28.6) | 46(33.1) |
high risk | 1 | 30(53.6) | 71(51.1) | ||
2 | 5(8.9) | 20(14.4) | |||
3 | 5(8.9) | 2(1.4) | |||
Modified PINK | Age (>60 vs. ≤60 years) Non-nasal type (yes vs. no) | / | 0 | 0 | 121(87.1) |
1 | 45(80.4) | 18(12.9) | |||
2 | 11(19.6) | 0 | |||
Modified IPI | Age (>60 vs. ≤60 years)ECOG score (≥2 vs. 0-1)Elevated LDH (yes vs. no)Extranodal involvement (≥2 vs. 0-1) | low risk | 0 | 2(3.6) | 6(4.3) |
1 | 16(28.6) | 46(33.1) | |||
high risk | 2 | 28(50.0) | 66(47.5) | ||
3 | 5(8.9) | 19(13.7) | |||
4 | 5(8.9) | 2(1.4) |
Conclusions
Advanced-stage non-nasal type NKTCL patients could achieve comparable prognosis with nasal cases after rational comprehensive therapy. Potent therapy is preferred in young patients with previously untreated disease, good performance status, and relatively low tumor burden.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Chinese Geriatric Oncology Society Scientific Research Fund (CGOS-06-2014-1-1-01600).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
485P - LDCT lung cancer screening of never-smokers meta-analysis subgroup analysis: Adenocarcinoma is the highly predictive histology identified in never-smokers
Presenter: Sai-Hong Ou
Session: Poster Display
Resources:
Abstract
486P - Fiscal feasibility and implications of integrating lung cancer screening into Hong Kong’s healthcare system
Presenter: Herbert Ho Fung Loong
Session: Poster Display
Resources:
Abstract
487P - Evaluating the performance of the USPSTF lung cancer screening guidelines in an Asian population of lung cancer patients
Presenter: Jian Wei Tan
Session: Poster Display
Resources:
Abstract
488P - Pulmonary ground glass opacity lesions: Immune ecosystem and its clinical relevances of early-stage lung adenocarcinoma
Presenter: Shensi Shen
Session: Poster Display
Resources:
Abstract
489TiP - BGB-LC-202 (NCT05577702): Phase II Umbrella study of tislelizumab (TIS) monotherapy and TIS-based immunotherapy combinations +/- chemotherapy (CT) as neoadjuvant treatment in Chinese patients (pts) with resectable stage II to IIIA non-small cell lung cancer (NSCLC)
Presenter: Wentao Yu
Session: Poster Display
Resources:
Abstract
491P - Furmonertinib as adjuvant therapy for elderly patients in resected EGFR-mutated non-small cell lung cancer: A double-center, real-world experience
Presenter: Ziheng Wu
Session: Poster Display
Resources:
Abstract
492P - Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: Preliminary results from a phase II study (ALTER-L043)
Presenter: Changli Wang
Session: Poster Display
Resources:
Abstract
493P - The prognostic value of 4L lymph node dissection in left-sided operable non-small cell lung cancer: A systematic review and meta-analysis
Presenter: Lei Peng
Session: Poster Display
Resources:
Abstract
495P - Intrinsic STING of CD8+T cells regulates self-metabolic reprogramming and exerts anti-tumor effects
Presenter: Qiuli Xu
Session: Poster Display
Resources:
Abstract
496P - Fruquintinib plus sintilimab in patients (pts) with advanced non-small cell lung cancer (NSCLC) with PD-L1-positive expression: A multicenter, single-arm phase II study
Presenter: Shun Lu
Session: Poster Display
Resources:
Abstract